Overview
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, where it was synthesized as a short version of the larger natural pineal extract Epithalamin. The Khavinson group has published extensively claiming telomerase activation, restoration of melatonin rhythms, and even reduced all-cause mortality in elderly Russian cohorts. The crucial methodological problem is that essentially all of the supportive clinical literature comes from a single research group, has not been replicated by independent Western or independent Russian laboratories, and uses methodology that would not pass modern regulatory review. Per Skill Rule 5 (old, unreplicated studies are weaker than they look), this entry holds Tier 4 for the headline longevity claim. This is the entry where the framework's editorial honesty is most tested.
Mechanism
Claimed mechanisms include direct telomerase activation, modulation of pineal melatonin secretion, epigenetic upregulation of antioxidant gene expression, and restoration of T-cell immune function in aged organisms. The molecular targets and pharmacokinetics are not characterized to modern standards. The peptide is small and would be expected to have very short systemic half-life with minimal direct CNS penetration — its proposed mechanisms via central pineal modulation strain biological plausibility for a peripherally administered tetrapeptide.
Evidence by indication
We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.
Longevity / lifespan extension
Khavinson and colleagues have published Russian clinical work claiming reduced all-cause mortality in elderly cohorts. The studies have small sample sizes, unclear randomization and blinding, no independent replication, and methodology that does not meet modern standards. By Skill Rule 5 and Rule 8, this is Tier 4. Do not soften.
Telomerase activation / telomere lengthening
In-vitro work (Khavinson lab) reports telomerase upregulation in human fibroblast cell lines. No independent replication of the in-vivo telomere-lengthening claim in humans. The mechanism would imply theoretical oncogenic risk if true at scale; the absence of replication is itself a relevant signal.
Sleep / melatonin rhythm restoration
Some small Russian clinical reports of sleep-architecture improvements in elderly subjects, plausibly mediated by claimed pineal effects. Not replicated; methodologically weak. Tier 3 only because the specific symptom claim is more proximal than the longevity claim.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Cancer / anti-tumor effects
Animal studies from the Khavinson group report reduced spontaneous tumor incidence in aged rodents. No human RCTs. Tier 3 for the animal-only claim; users seeking an anti-cancer benefit have no human evidence to act on.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Studied dose ranges
The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.
Khavinson-protocol courses are described as 5–10 mg SubQ daily for 10–20 days, repeated 1–2× per year. Note unit math: 10 mg = 10,000 mcg. These dosing conventions originate from Russian clinical reports and are not validated outside that body of work.
Contraindications
- Active malignancy — telomerase activation, if real, is theoretically pro-tumorigenic; absence of evidence cuts both ways here
- Pregnancy and breastfeeding (no human safety data)
- Known hypersensitivity to peptide formulations or excipients
Reported side effects
- Injection-site reactions
- No published Western adverse-event surveillance
- Long-term human safety data is essentially absent
- Theoretical concern: if telomerase activation occurs as claimed, the long-term oncological implications are unstudied
Reconstitution & storage
Lyophilized powder reconstituted with bacteriostatic water. A 10 mg vial in 5 mL BAC water = 2 mg/mL, making a 5 mg dose = 2.5 mL (a large SubQ volume; many users split across two injections). Use the calculator to verify; concentration varies by vendor.
Storage. Lyophilized: refrigerate. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.
Editorial note
DRAFT — pending Wayne's review. This is the entry that proves the framework. Epithalon is one of the most over-claimed compounds in the longevity-peptide world, and the entirety of the supporting clinical evidence comes from a single research group, with methodology that would not survive a modern peer review. Per Skill Rule 5 (old/unreplicated studies are weaker than they look) and Rule 10 (when in doubt, downgrade), the headline longevity claim sits at Tier 4. The job here is editorial honesty, not consensus — competitor apps will be soft on this; we will not be.
Citations
- [1]Effect of bioregulators on key indicators of biological age and survival of older peopleKhavinson VKh, Morozov VG. · Bulletin of Experimental Biology and Medicine / Russian-translated literature · 2003 · PMID 12937538Anchor citation for the longevity claim — included specifically to be evaluated under Skill Rule 5 (single-lab, unreplicated, methodologically weak).View source
- [2]Peptide promotes overcoming of the division limit in human somatic cellKhavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. · Bulletin of Experimental Biology and Medicine · 2003 · PMID 14523375In-vitro telomerase / Hayflick-limit claim; the mechanistic basis for the most-cited longevity narrative.View source